tirzepatide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Tirzepatide 15 mg/MTD produced greater reductions in BMI (MD −7.21 kg/m2; 95% CI −8.79 to −5.63; p < 0.00001; I 2 = 96%) and waist circumference (MD −14.27 cm; 95% CI −15.43 to −13.10; p < 0.00001; I 2 = 23%) versus placebo.”
Quoted verbatim from Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 15 mg or maximum tolerated dose, once weekly
- Population
- Adults with obesity or overweight without diabetes, pooled across SURMOUNT placebo-controlled trials
Effect -7.21 mean difference, 95% CI -8.79 to -5.63
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.2026PMID:42487213Permalink
Keep reading
- Everything the graph holds on tirzepatide
- Every compound studied against Body mass index
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45MMZH3ECXDCSH6XP0PM9B9